Showing results (741-750 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|August 9, 2020
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trialPauline D J Bollen, Cecilia L Moore, Hilda A Mujuru, et al.
The Lancet. HIV|August 9, 2020
Modern diagnostic technologies for HIVNitika Pant Pai, Angela Karellis, John Kim, et al.
The Lancet. HIV|April 7, 2015
Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysisJennifer A Smith, Monisha Sharma, Carol Levin, et al.
The Lancet. HIV|October 5, 2018
Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control studySeth C Inzaule, Raph L Hamers, Marc Noguera-Julian, et al.
The Lancet. HIV|September 18, 2018
Dynamics of the HIV outbreak and response in Scott County, IN, USA, 2011-15: a modelling studyGregg S Gonsalves, Forrest W Crawford
The Lancet. HIV|April 30, 2022
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trialTheodore D Ruel, Edward P Acosta, Jessica P Liu, et al.
The Lancet. HIV|April 1, 2021
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR studyChloe Orkin, Shinichi Oka, Patrick Philibert, et al.
The Lancet. HIV|May 11, 2023
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trialLameck Chinula, Lauren Ziemba, Sean Brummel, et al.
The Lancet. HIV|May 13, 2023
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunitiesJessica E Haberer, Andrew Mujugira, Kenneth H Mayer
The Lancet. HIV|April 29, 2023
The HIV care continuum for sexually active transgender women in three metropolitan municipalities in South Africa: findings from a biobehavioural survey 2018-19Allanise Cloete, Musawenkosi Mabaso, Helen Savva, et al.
Pageof 79